Lung Cancer: Page 3

Foundation Medicine, lung cancer groups partner in screening trial
By LabPulse.com staff writers
The trial, named the "LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer" (LEADER), is the fourth study conducted through LCMC and a collaborative effort involving multiple academic study sites and pharmaceutical firms.
June 2, 2022
2022 06 03 17 12 0335 Cancer Lung 3 D Black 400
Lucence promotes lung cancer research at ASCO 2022
By LabPulse.com staff writers
In three separate poster presentations, Lucence will share data showing how a total nucleic acid approach combining circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) in one liquid biopsy test could increase actionable molecular information in lung cancer patients, according to the company.
May 31, 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
CorePath and Cizzle partner to develop lung cancer test
By LabPulse.com staff writers
The companies said they will first focus on offering the proprietary test in the U.S., where lung cancer accounts for 25% of all cancer deaths.
May 25, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Biomarker data improves CT lung cancer screening's bottom line
By Kate Madden Yee
The findings suggest a way to make CT lung cancer screening not only more useful but also economical when it comes to patient outcomes, wrote a team led by Zixuan Zhao, PhD, of Zhejiang University in Hangzhou, China.
May 23, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Delfi enrolls first participants in liquid biopsy lung cancer trial
By LabPulse.com staff writers
The CASCADE-LUNG study is expected to enroll 15,000 patients and aims to clinically validate Delfi's test, which detects a blood-based signal of undiagnosed lung cancer. It is a prospective, multicenter trial that will enroll participants at the time of their low-dose computed tomography (LDCT) lung cancer scans.
May 8, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Guardant highlights data on multicancer test at AACR 2022
By LabPulse.com staff writers
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
2017 09 14 23 05 1167 Cancer Cell 400
Biodesix NGS test highlighted in study
By LabPulse.com staff writers
The company said the test can assay for major variant classes, which includes actionable mutations in support of comprehensive molecular testing in lung cancer.
March 31, 2022
2020 06 18 17 24 6922 Immunoassay Analysis 400
Optellum's Virtual Nodule Clinic receives CE Mark
By LabPulse.com staff writers
Virtual Nodule Clinic is an AI-powered clinical decision support software tool designed to help clinicians identify and track at-risk patients who present suspicious lung nodules that may or may not be cancerous.
March 30, 2022
2021 08 18 23 12 2135 Computer Ai Artificial Illustration 400
Insightec to launch new trials of Exablate Neuro
By LabPulse.com staff writers
One study will evaluate the use of Exablate Neuro to treat patients with primary non-small cell lung cancer that has metastasized to the brain in conjunction with Keytruda, a humanized antibody immunotherapy. Exablate Neuro could be used to open up the blood-brain barrier to make immunotherapy agents like Keytruda more effective.
March 9, 2022
2022 03 10 18 19 1134 Mri Head 400
Invitae launches 2 IVD cancer tests in Europe
By LabPulse.com staff writers
Both tests offer comprehensive genomic profiling and companion diagnostic use for solid tumor neoplasms, including non-small cell lung cancer, in tissue biopsy and where tissue is a limiting factor.
February 15, 2022
2022 01 12 21 29 6223 Europe Signpost 400
PierianDx, Biodesix partner on lung cancer diagnostics
By LabPulse.com staff writers
PierianDx will provide its interpretation technology platform for use with Biodesix's newly launched GeneStrat NGS genomic test, a blood-based tumor profiling test that detects mutations -- including EGFR, ALK, and KRAS -- in patients with non-small cell lung cancer (NSCLC).
January 18, 2022
2019 09 05 21 14 7857 Heart Pulmonary Trunk 400
Lucence offers expanded cfRNA version LiquidHallmark
By LabPulse.com staff writers
Researchers have found that adding RNA sequencing to DNA sequencing for tissue testing yields an additional 14% of "clinically actionable alterations," Lucence said. An internal study conducted by the firm found that "out of 112 non-small cell lung cancer samples, 29 fusions were detected with a combined cfDNA and cfRNA approach in plasma, compared with 20 fusions from cfDNA alone."
January 9, 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
Previous Page
Page 3 of 7
Next Page